Opthea Limited (NASDAQ: OPT)
$2.14
+0.0500 ( +2.39% ) 18.3K
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Market Data
Open
$2.14
Previous close
$2.09
Volume
18.3K
Market cap
$191.60M
Day range
$2.04 - $2.18
52 week range
$1.60 - $4.40
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 4 | Apr 30, 2024 |
6-k | Quarterly Reports | 4 | Apr 25, 2024 |
6-k | Quarterly Reports | 4 | Apr 09, 2024 |
6-k | Quarterly Reports | 4 | Apr 05, 2024 |
6-k | Quarterly Reports | 33 | Apr 05, 2024 |
6-k | Quarterly Reports | 4 | Apr 04, 2024 |
6-k | Quarterly Reports | 48 | Apr 03, 2024 |
6-k | Quarterly Reports | 4 | Mar 19, 2024 |
6-k | Quarterly Reports | 4 | Mar 06, 2024 |
6-k | Quarterly Reports | 32 | Mar 04, 2024 |